ANNAPOLIS, MD – In an era where precision medicine and patient-led advocacy are converging to reshape the oncology landscape, METAVIVOR, a leading non-profit organization dedicated to metastatic breast cancer (MBC) research, has officially announced the opening of its 2026 grant cycle. The announcement, delivered by the organization’s president, Dr. Kelly Shanahan, underscores a pivotal moment for the MBC community as it grapples with an unprecedented surge in research interest, the complexities of clinical trial participation, and the ongoing quest for sustainable federal funding.
The 2026 cycle follows a year of record-breaking engagement, during which the organization received double its typical volume of Letters of Intent (LoIs). This surge reflects a growing scientific focus on Stage IV breast cancer—a field that has historically been underfunded in favor of early-detection and prevention studies. As Dr. Shanahan navigates her own journey as both a physician and a patient currently enrolled in a clinical trial, the organization’s call for researchers and peer reviewers highlights the urgent need for collaborative, patient-centered innovation.
Main Facts: The 2026 Grant Cycle and the Drive for Specialized Research
The core of METAVIVOR’s mission is the funding of "translational" research—studies that can be moved quickly from the laboratory to the clinical setting to extend the lives of those living with MBC. The opening of the 2026 grant cycle represents a critical opportunity for scientists specializing in metastatic disease to secure funding that is often elusive through traditional channels.
A Surge in Scientific Interest
Last year’s doubling of LoIs indicates a shift in the academic and clinical research community. More researchers are turning their attention toward the mechanisms of metastasis—the process by which cancer spreads to vital organs such as the bones, liver, lungs, and brain. METAVIVOR’s unique model, which directs 100% of all donations toward research grants, has made it a cornerstone for scientists who are often overlooked by larger funding bodies that prioritize primary prevention.
The Peer Review Process: Bridging the Gap
A distinctive feature of the METAVIVOR grant process is the inclusion of both scientists and patients in the review of applications. By involving those who live with the disease daily, the organization ensures that the research funded is not only scientifically rigorous but also meaningful to the patient population. Dr. Shanahan’s recent call for volunteers emphasizes the need for diverse perspectives to evaluate the clinical utility and quality-of-life implications of proposed studies.
Spotlight on Oligometastatic HER2+ Research
Among the highlights of the current cycle is the promotion of a new trial led by Dr. Lior Braunstein at Memorial Sloan Kettering (MSK) Cancer Center. This study investigates the potential benefits of aggressive intervention for patients with "oligometastatic" HER2+ MBC—a state where the cancer has spread to only a limited number of sites. The trial seeks to determine if adding surgery to remove the primary breast tumor and applying radiation to metastatic sites can significantly improve long-term outcomes, a departure from the traditional "systemic-only" treatment approach for Stage IV patients.
Chronology: The Evolution of MBC Advocacy and Funding
To understand the significance of the 2026 grant cycle, one must look at the trajectory of metastatic breast cancer advocacy over the last two decades.
- The Early 2000s: The "Pink" Gap: For years, breast cancer awareness was dominated by the "pink ribbon" movement, which focused heavily on early detection and "survivorship." Patients whose cancer had already metastasized often felt marginalized, as their condition was considered incurable and research funding for Stage IV was disproportionately low (estimated at less than 7% of total breast cancer research funding).
- 2009: The Founding of METAVIVOR: Established by a small group of patients, METAVIVOR began as a grassroots effort to ensure that MBC received dedicated research dollars. The organization’s commitment to funding only metastatic research set a new standard in the non-profit sector.
- 2020–2024: The Era of Breakthroughs: The introduction of CDK4/6 inhibitors, antibody-drug conjugates (ADCs), and targeted therapies for HER2-low patients transformed the treatment landscape. However, as more patients lived longer with the disease, the need for research into resistance mechanisms and "financial toxicity" became more apparent.
- Present Day: The 2026 grant cycle opens against a backdrop of economic uncertainty and a proposed increase in the National Institutes of Health (NIH) and National Cancer Institute (NCI) budgets. The community is currently waiting to see if federal promises of increased funding will materialize, making private funding from organizations like METAVIVOR more vital than ever.
Supporting Data: The Socio-Economic and Clinical Reality of MBC
The urgency behind METAVIVOR’s fundraising and grant initiatives is supported by sobering statistics regarding the prevalence and cost of metastatic disease.
Survival and Incidence
While 5-year survival rates for localized breast cancer are near 99%, the rate for metastatic breast cancer remains approximately 30%. In the United States, an estimated 42,000 people die from MBC every year. Despite these numbers, the "metastatic" stage is the only stage of breast cancer that kills, yet it continues to receive a minority of research funding relative to its mortality rate.
The "Financial Toxicity" of Clinical Trials
Dr. Shanahan’s personal account of traveling from California to Nashville, Tennessee, for a clinical trial at the Sarah Cannon Research Institute brings to light the "financial and time toxicity" inherent in modern oncology.
- Travel Costs: For many patients, the most promising treatments are only available at specific "Centers of Excellence," requiring cross-country flights, hotel stays, and time away from work and family.
- The Geographic Barrier: Research indicates that patients living in rural areas or far from major research hubs are significantly less likely to enroll in clinical trials, often due to the prohibitive costs of logistics rather than medical ineligibility.
Federal Funding Trends
The NCI’s budget has seen incremental increases, but the competition for federal R01 grants remains fierce. Historically, only about 10-15% of high-quality research applications receive NCI funding. This gap is where METAVIVOR steps in, providing the "seed money" that allows researchers to gather enough data to eventually qualify for larger federal grants.
Official Responses: Voices from the Front Lines
The leadership at METAVIVOR and the researchers they support emphasize that the fight against MBC is as much about community and policy as it is about biology.
Dr. Kelly Shanahan, President of METAVIVOR:
"We cannot do the work we do without you, our supporters," Shanahan stated, emphasizing the reliance on grassroots fundraising. Her dual role as a physician and a trial participant provides a unique perspective on the operational hurdles of cancer centers. "I’m enjoying seeing how a different cancer center operates… but flying across the country is both financially and time toxic." Her experience underscores the organization’s push for more decentralized trial sites, such as the eventual expansion of the MSK trial.
Scientific Community Perspective:
Dr. Lior Braunstein’s work at Memorial Sloan Kettering represents a shift toward "aggressive local therapy" for metastatic patients. By engaging with METAVIVOR, researchers like Braunstein are able to tap into a motivated patient population that is eager to prove that Stage IV does not always mean "palliative care only." The trial’s focus on HER2+ patients—a subgroup that has seen some of the most dramatic improvements in survival—aims to push the envelope toward a possible "cure" or long-term remission for oligometastatic patients.
Implications: The Future of MBC Care and Advocacy
The activities surrounding the 2026 grant cycle have profound implications for the future of oncology and patient support systems.
1. The Redefinition of "Metastatic"
If trials like the one at MSK prove successful, the medical community may have to redefine how it categorizes and treats oligometastatic disease. Moving away from a "systemic-only" approach to one that includes surgery and radiation for Stage IV could fundamentally change the standard of care, offering hope for long-term survival that was previously unthinkable.
2. Addressing Systemic Barriers to Trials
Dr. Shanahan’s advocacy for transferring to trial sites closer to home highlights a systemic need for "trial decentralization." If clinical trials remain concentrated in a few major cities, the data generated will lack diversity, and the treatments will remain inaccessible to the average patient. METAVIVOR’s influence could potentially pressure pharmaceutical companies and research institutes to prioritize site expansion.
3. The Power of Peer-to-Peer Support
Beyond research, METAVIVOR’s expansion of peer-to-peer support groups led by trained volunteers addresses the psychological toll of the disease. As treatment becomes more complex, the "navigator" role played by fellow patients becomes essential for maintaining mental health and treatment adherence.
4. The Sustainability of Grassroots Funding
With the 2026 fundraisers already being planned, the organization is calling for a new wave of community engagement. The reliance on individual donors and local events (walks, galas, and online campaigns) remains the lifeblood of MBC research. The success of these fundraisers will directly determine how many of the record-breaking LoIs can be converted into fully funded studies.
In conclusion, the 2026 METAVIVOR grant cycle is more than just a financial window; it is a barometer for the state of metastatic breast cancer research. As patients like Dr. Shanahan bridge the gap between the clinic and the laboratory, the message remains clear: while the weather of research funding may be as unpredictable as a Tahoe snowstorm, the commitment of the MBC community to finding a cure is unwavering. For researchers, patients, and supporters alike, the path forward is paved with rigorous science, personal sacrifice, and an enduring hope for a future where metastatic breast cancer is a manageable chronic condition rather than a terminal diagnosis.
About the Author
